RESUMEN
This study describes the preparation of a cylindrical polymer foam column termed Chitosan/ß-Cyclodextrin/MIL-68(Al) (CS/ß-CD/MIL-68(Al)). An ice template-freeze drying technique was employed to prepare the CS/ß-CD/MIL-68(Al) foam column by embedding MIL-68(Al) in a polymer matrix comprising cross-linked chitosan (CS) and ß-cyclodextrin (ß-CD). The cylindrical CS/ß-CD/MIL-68(Al) foam was subsequently inserted into a syringe to develop a solid phase extraction (SPE) device. Without the requirement for an external force, the sample solution passed easily through the SPE column thanks to the porous structure of the CS/ß-CD/MIL-68(Al) foam column. Moreover, the CS/ß-CD/MIL-68(Al) foam column was thought to be a superior absorbent for SPE since it included the adsorptive benefits of CS, ß-CD, and MIL-68(Al). The SPE was utilized in conjunction with high-performance liquid chromatography to analyze six sulfonamides found in milk, urine, and water. With matrix effects ranging from 80.49 % to 104.9 % with RSD values of 0.4-14.0 %, the method showed high recoveries ranging from 80.6 to 107.4 % for water samples, 93.4-105.2 % for urine, and 87.4-100.9 % for milk. It also demonstrated good linearity in the range of 10-258 ng·mL-1 with the limits of detection ranging from 1.88 to 2.58 ng·mL-1. The cylindrical CS/ß-CD/MIL-68(Al) foam column prepared in this work offered several advantages, including its simple fabrication, excellent water stability, absence of pollutants, biodegradability, and reusability. It is particularly well-suited for SPE. Furthermore, the developed SPE method, employing CS/ß-CD/MIL-68(Al) foam column, is straightforward and precise, and its benefits, including affordability, ease of preparation, lack of specialized equipment, and solvent economy, underline its broad applicability for the pretreatment of aqueous samples.
Asunto(s)
Quitosano , Límite de Detección , Estructuras Metalorgánicas , Leche , Extracción en Fase Sólida , Sulfonamidas , beta-Ciclodextrinas , Extracción en Fase Sólida/métodos , Quitosano/química , beta-Ciclodextrinas/química , Leche/química , Estructuras Metalorgánicas/química , Sulfonamidas/orina , Sulfonamidas/aislamiento & purificación , Sulfonamidas/química , Animales , Cromatografía Líquida de Alta Presión/métodos , Contaminantes Químicos del Agua/aislamiento & purificación , Contaminantes Químicos del Agua/análisis , Contaminantes Químicos del Agua/química , Humanos , Reproducibilidad de los ResultadosRESUMEN
Cimicoxib is a selective COX-2 inhibitor (coxib) registered for the treatment of pain and inflammation in dogs. Pharmacokinetics of some coxibs have been described in dogs and cats. In cats, total body clearance values are lower and terminal half-lives of the coxibs are longer than those in dogs. The aim of this work was to evaluate if this is also the case for cimicoxib. For this purpose, blood pharmacokinetics and urinary excretion after IV administration were compared between these species. The in vitro metabolism of cimicoxib was also evaluated using canine and feline microsomes. In canine and feline microsomes, the formation rate of demethyl-cimicoxib, a phase 1 metabolite, was decreased in presence of quinidine, a specific human cytochrome P450 (CYP)2D6 inhibitor. IC50 values were 1.6 µM and 0.056 µM with canine and feline microsomes, respectively. As quinidine was about 30 times more potent in feline microsomes, the affinity of cimicoxib to the enzyme was considered to be about 30 times lower than that in canine microsomes. Total body clearance (ClB) of cimicoxib, was 0.50 L/h kg in dogs and 0.14 L/h kg in cats (P < 0.01) and terminal half-life, T½λz, was 1.92 and 5.25 h, respectively (P < 0.01). Dose eliminated in urine was 12.2% in dogs and 3.12% in cats (P < 0.01). Conjugated demethyl-cimicoxib represented 93.7% of this amount in dogs and 67.5% in cats. Thus cimicoxib, like other veterinary coxibs, was eliminated more slowly in cats. Both CYP2D15 (the canine ortholog of CYP2D6) and UDP-glucuronyltransferase enzyme systems have reduced ability to produce metabolites of cimicoxib in cats.
Asunto(s)
Gatos/metabolismo , Inhibidores de la Ciclooxigenasa 2/farmacocinética , Perros/metabolismo , Imidazoles/farmacocinética , Sulfonamidas/farmacocinética , Administración Intravenosa/veterinaria , Animales , Hidrocarburo de Aril Hidroxilasas/antagonistas & inhibidores , Hidrocarburo de Aril Hidroxilasas/metabolismo , Gatos/orina , Inhibidores de la Ciclooxigenasa 2/administración & dosificación , Inhibidores de la Ciclooxigenasa 2/orina , Inhibidores Enzimáticos del Citocromo P-450/farmacología , Perros/orina , Imidazoles/administración & dosificación , Imidazoles/orina , Microsomas Hepáticos/metabolismo , Quinidina/farmacología , Especificidad de la Especie , Sulfonamidas/administración & dosificación , Sulfonamidas/orinaRESUMEN
BACKGROUND: Aprocitentan is an orally active, dual endothelin receptor antagonist that may offer a new therapeutic option for the treatment of difficult-to-control hypertension. OBJECTIVE: To investigate safety, tolerability, mass balance, absorption, distribution, metabolism, and excretion of aprocitentan. METHODS: In this single-center, open-label study, a single oral dose of 25 mg containing 3.7 MBq of 14C-radiolabeled aprocitentan was administered to 6 healthy male subjects. Metabolites were identified using mass spectrometry and, where possible, confirmed and quantified with reference compounds. RESULTS: Aprocitentan was well tolerated and there were no clinically significant findings for any safety variable. The geometric mean cumulative recovery of radioactivity from urine and feces over 14 days was 77% of the administered radioactive dose, with 52.1% cumulative recovery from urine and 24.8% from feces. Concentrations of total radioactivity in whole blood were markedly lower compared to plasma. In plasma, 94.3% of total radioactivity was aprocitentan. In urine and feces, 5 and 2, respectively (in feces one being aprocitentan) main products were identified. Metabolism data of aprocitentan identified two main elimination pathways, glucosidation to M3 and hydrolysis to M1, representing approximately 25% and 32% of the radioactive dose, respectively. CONCLUSIONS: Based on these metabolism data, aprocitentan can be concomitantly administered without dose adjustment with drugs that are inhibitors or inducers of any metabolizing enzyme, specifically cytochrome P450 enzymes.
Asunto(s)
Antagonistas de los Receptores de Endotelina/metabolismo , Antagonistas de los Receptores de Endotelina/farmacología , Hipertensión/tratamiento farmacológico , Pirimidinas/metabolismo , Pirimidinas/farmacología , Sulfonamidas/metabolismo , Sulfonamidas/farmacología , Administración Oral , Anciano , Antagonistas de los Receptores de Endotelina/sangre , Antagonistas de los Receptores de Endotelina/orina , Humanos , Masculino , Persona de Mediana Edad , Pirimidinas/sangre , Pirimidinas/orina , Sulfonamidas/sangre , Sulfonamidas/orinaRESUMEN
In this study, a microbiological inhibition method for rapidly screening antibiotics in swine urine was established with an easy sample pre-treatment. The microbiological system consisted of an agar medium mixed with nutrients, sensitizers, a test bacterium (Geobacillus stearothermophilus ATCC12980) and pH indicator (bromocresol purple). It was observed that the detection limits of the test kit for twenty-eight common antimicrobial residues in urine, including ß-lactams, aminoglycosides, tetracyclines, sulfonamides, macrolides, and lincosamides, were less than or equal to the maximum residue limits of the kidney, as determined by the EU and China. Moreover, the false negative rate and the false positive rate, along with other performance indexes such as interassay coefficients of variation and shelf life of the kit, all met the standard requirements of the ISO13969:2003 guidelines. Additionally, our results were consistent with those using the gold-standard physical chemistry method, which suggest the proposed method is suitable for screening antibiotic residues.
Asunto(s)
Antibacterianos/orina , Residuos de Medicamentos/análisis , Ensayos Analíticos de Alto Rendimiento/métodos , Drogas Veterinarias/orina , Aminoglicósidos/farmacología , Aminoglicósidos/orina , Animales , Antibacterianos/análisis , Antibacterianos/farmacología , Medios de Cultivo , Reacciones Falso Negativas , Reacciones Falso Positivas , Contaminación de Alimentos/análisis , Geobacillus stearothermophilus/efectos de los fármacos , Límite de Detección , Macrólidos/farmacología , Macrólidos/orina , Sensibilidad y Especificidad , Sulfonamidas/farmacología , Sulfonamidas/orina , Porcinos , Tetraciclinas/farmacología , Tetraciclinas/orina , Drogas Veterinarias/farmacologíaRESUMEN
BACKGROUND: Surufatinib is a potent small-molecule tyrosine kinase inhibitor and exhibited significant efficacy in the treatment of neuroendocrine tumors in clinical trials. OBJECTIVE: The absorption, metabolism and excretion of surufatinib were investigated in rats and human volunteers following a single oral dose of [14C] surufatinib. METHODS: The radioactivity was measured in plasma, urine, feces and bile by liquid scintillation counting, and the metabolites were characterized by liquid chromatography coupled to mass spectrometry. RESULTS: Surufatinib was orally absorbed similarly in rats and human volunteers, with the median Tmax of 4 hours post-dose. The estimated t1/2 appeared longer in humans than in rats (mean t1/2: 3.12 hour for male rats, 6.48 hours for female rats and 23.3 hours for male human volunteers). The excretion of surufatinib was almost complete in rats and human volunteers in the studies, with the total radioactivity recovery of >90% of the dose. Similarly, in rats and humans, fecal excretion predominated (approximately 87% of the dose recovered in feces and only 5% in urine). The parent drug was the major radioactive component detected in the plasma extracts of rats and humans, and no single circulating metabolite accounted for >10% of the total radioactivity. Unchanged drug was a minor radioactive component in the excreta of rats and humans. CONCLUSION: Fecal excretion was the predominant way for the elimination of surufatinib and its metabolites in rats and humans. No disproportionate circulating metabolite was observed in humans.
Asunto(s)
Antineoplásicos/farmacocinética , Indoles/farmacocinética , Inhibidores de Proteínas Quinasas/farmacocinética , Pirimidinas/farmacocinética , Sulfonamidas/farmacocinética , Administración Oral , Adulto , Animales , Antineoplásicos/efectos adversos , Antineoplásicos/orina , Bilis/metabolismo , Heces/química , Femenino , Humanos , Indoles/efectos adversos , Indoles/orina , Absorción Intestinal , Masculino , Inhibidores de Proteínas Quinasas/efectos adversos , Inhibidores de Proteínas Quinasas/orina , Pirimidinas/efectos adversos , Pirimidinas/orina , Ratas Sprague-Dawley , Sulfonamidas/efectos adversos , Sulfonamidas/orinaRESUMEN
A novel method using UPLC with tandem mass-spectrometric detection (UPLC-MS/MS) with positive electrospray ionization was developed for the detection of the antiarrhythmic drug, dofetilide, in mouse plasma and urine. Protein precipitation was performed on 10 µL of plasma and 2 µL of urine samples using dofetilide-D4 as an internal standard, and separation of the analyte was accomplished on a C18 analytical column with the flow of 0.40 mL/min. Subsequently, the method was successfully applied to determine the pharmacokinetic parameters of dofetilide following oral and intravenous administration. The calibration curve was linear over the selected concentration range (R2 ≥ 0.99), with a lower limit of quantitation of 5 ng/mL. The intra-day and inter-day precisions, and accuracies obtained from a 5-day validation ranged from 3.00 to 7.10%, 3.80-7.20%, and 93.0-106% for plasma, and 3.50-9.00%, 3.70-10.0%, 87.0-106% for urine, while the recovery of dofetilide was 93.7% and 97.4% in plasma and urine, respectively. The observed pharmacokinetic profiles revealed that absorption is the rate-limiting step in dofetilide distribution and elimination. Pharmacokinetic studies illustrate that the absolute bioavailability of dofetilide in the FVB strain mice is 34.5%. The current developed method allows for accurate and precise quantification of dofetilide in micro-volumes of plasma and urine, and was found to be suitable for supporting in vivo pharmacokinetic studies.
Asunto(s)
Cromatografía Líquida de Alta Presión/métodos , Fenetilaminas/sangre , Fenetilaminas/orina , Plasma/química , Sulfonamidas/sangre , Sulfonamidas/orina , Espectrometría de Masas en Tándem/métodos , Animales , Disponibilidad Biológica , Líquidos Corporales/química , Calibración , Límite de Detección , Masculino , Ratones , Fenetilaminas/farmacocinética , Sulfonamidas/farmacocinéticaRESUMEN
Nowadays routine residue monitoring involves the analysis of many compounds from different classes, mainly in urine. In the past two decades, developments heavily focused on the use of mass spectrometers (MS) and faster and more sensitive MS detectors have reached the market. However, chromatographic separation (CS) was rather ignored and the cognate developments in CS were not in line. As a result, residue analysis did not improve to the extent anticipated. CS by LC x LC is a promising technique and will enable a further increase in the range of compounds and compound classes that can be detected in a single run. In the present study, a self-built LC x LC system, using a 10 port valve, was connected to a single quadrupole MS with electrospray interface. Standards containing a mixture of sulphonamides, ß-agonists and (steroid) hormones, 53 compounds, in total, were analysed. Results demonstrated that these compounds were well separated and could be detected at low levels in urine, i.e. limit of detection (LOD) from 1 µg L-1 for most ß-agonists to 10 µg L-1 for some sulphonamides and most hormones. To enhance the sensitivity, optimisation was performed on an advanced commercial LC x LC system connected to a full scan accurate MS. This ultimately resulted in a fast high throughput untargeted method, including a simple sample clean-up in a 96-well format, for the analysis of urine samples.
Asunto(s)
Agonistas Adrenérgicos beta/orina , Contaminación de Alimentos/análisis , Esteroides/orina , Sulfonamidas/orina , Animales , Bovinos , Cromatografía Liquida , Femenino , Masculino , Espectrometría de Masas , Factores de TiempoRESUMEN
OBJECTIVE: The aim of this study was to summarise the pharmacokinetic findings from eight phase I studies in healthy volunteers given oral AZD5069, a selective small-molecule CXCR2 antagonist. METHODS: 240 healthy volunteers across eight phase I studies received single (0.1-200 mg) or multiple once- or twice-daily (10-120 mg) oral AZD5069 as solution, suspension, capsules or tablets. Pharmacokinetics were evaluated using non-compartmental analysis methods. RESULTS: AZD5069 was rapidly absorbed (time to maximum concentration ~ 2 h) under fasting conditions. A high-fat, high-calorie meal delayed and reduced the peak plasma AZD5069 concentration (Cmax) by 50%, but total exposure (AUC) was unchanged (fed:fasting geometric mean ratio 90% confidence interval within 0.80-1.25). The plasma concentration of AZD5069 declined with an initial half-life of 4 h and terminal half-life of 11 h. Steady-state plasma concentrations were achieved within 2-3 days and accumulation was ~ 1.1-fold with twice-daily dosing. Systemic exposure was approximately proportional to dose. Intra- and inter-subject variability in AUC was 3-11 and 29-64%, respectively. Less than 5% of the AZD5069 dose was excreted as parent drug in the urine. Elderly subjects had 39% higher AZD5069 AUC and 21% higher Cmax than younger adults. Japanese subjects had similar or slightly higher exposure to AZD5069 than Caucasian subjects. Co-administration with ketoconazole resulted in 2.1-fold higher AUC and 1.6-fold higher Cmax. All formulations had similar bioavailability. CONCLUSIONS: AZD5069 demonstrated predictive linear pharmacokinetics with low intra- and moderate inter-subject variability and no major influences from ethnicity, age, food or formulation. Half-life data indicated suitability for twice-daily dosing. CLINICALTRIALS. GOV IDENTIFIERS: NCT00953888, NCT01051505, NCT01083238, NCT01100047, NCT01332903, NCT01480739, NCT01735240, NCT01989520.
Asunto(s)
Pirimidinas/farmacocinética , Sulfonamidas/farmacocinética , Adolescente , Adulto , Factores de Edad , Anciano , Disponibilidad Biológica , Cápsulas/farmacocinética , Ensayos Clínicos Fase I como Asunto , Relación Dosis-Respuesta a Droga , Interacciones Farmacológicas , Femenino , Interacciones Alimento-Droga , Voluntarios Sanos , Humanos , Cetoconazol/farmacología , Masculino , Persona de Mediana Edad , Pirimidinas/sangre , Pirimidinas/orina , Soluciones/farmacocinética , Sulfonamidas/sangre , Sulfonamidas/orina , Suspensiones/farmacocinética , Comprimidos/farmacocinética , Adulto JovenRESUMEN
A specific and sensitive method was firstly developed using high performance liquid chromatography coupled with tandem mass spectrometry (HPLC-MS/MS) to simultaneously quantify TPN729 and its metabolites (TPN729-D1, TPN729-D2, TPN729M15-3 and TPN729M3) in human plasma and (TPN729-D1, TPN729-D2, TPN729M15-3 and TPN729M14) in human urine. Protein precipitation and direct dilution were used to extract TPN729 and its metabolites from plasma and urine, respectively. Ionization of TPN729, TPN729-D1, TPN729-D2, TPN729M15-3, TPN729M3, TPN729M14 and sildenafil (internal standard, IS) was performed using an electrospray ionization (ESI) source in positive mode and detection was carried out with multiple reaction monitoring (MRM) mode. This assay method for TPN729 and its five metabolites has been fully validated in terms of sensitivity, linearity, lower limit of quantification (LLOQ), precision, accuracy, stability, matrix effect and recovery. The LLOQ of TPN729/TPN729-D1/TPN729-D2/TPN729M15-3/TPN729M3 in human plasma and TPN729/TPN729-D1/TPN729-D2/TPN729M15-3/TPN729M14 in human urine were 0.200/0.500/2.00/0.500/1.00â¯ng/mL and 4.00/2.50/10.0/2.50/1.00â¯ng/mL, respectively. Inter- and intra-batch precision of TPN729 and its metabolites were less than 15% and the accuracy was within ±15% for both plasma and urine. The extraction recoveries of all analytes at three concentration levels were consistent. In conclusion, the validation results showed that this method was robust, specific, and sensitive and it can successfully fulfill the requirement of clinical pharmacokinetic study of TPN729 in Chinese healthy subjects.
Asunto(s)
Pirimidinonas/sangre , Pirimidinonas/orina , Sulfonamidas/sangre , Sulfonamidas/orina , Espectrometría de Masas en Tándem/métodos , Biomarcadores/sangre , Biomarcadores/orina , Cromatografía Líquida de Alta Presión/métodos , Cromatografía Liquida/métodos , HumanosRESUMEN
Dual-cloud point extraction (dCPE) was successfully developed for simultaneous extraction of trace sulfonamides (SAs) including sulfamerazine (SMZ), sulfadoxin (SDX), sulfathiazole (STZ) in urine and water samples. Several parameters affecting the extraction were optimized, such as sample pH, concentration of Triton X-114, extraction temperature and time, centrifugation rate and time, back-extraction solution pH, back-extraction temperature and time, back-extraction centrifugation rate and time. High performance liquid chromatography (HPLC) was applied for the SAs analysis. Under the optimum extraction and detection conditions, successful separation of the SAs was achieved within 9min, and excellent analytical performances were attained. Good linear relationships (R2≥0.9990) between peak area and concentration for SMZ and STZ were optimized from 0.02 to 10µg/mL, for SDX from 0.01 to 10µg/mL. Detection limits of 3.0-6.2ng/mL were achieved. Satisfactory recoveries ranging from 85 to 108% were determined with urine, lake and tap water spiked at 0.2, 0.5 and 1µg/mL, respectively, with relative standard deviations (RSDs, n=6) of 1.5-7.7%. This method was demonstrated to be convenient, rapid, cost-effective and environmentally benign, and could be used as an alternative tool to existing methods for analysing trace residues of SAs in urine and water samples.
Asunto(s)
Antiinfecciosos/análisis , Antiinfecciosos/orina , Cromatografía Líquida de Alta Presión/métodos , Sulfonamidas/análisis , Sulfonamidas/orina , Contaminantes Químicos del Agua/análisis , Contaminantes Químicos del Agua/orina , Fraccionamiento Químico/métodos , Agua Potable/análisis , Humanos , Lagos/análisis , Límite de Detección , Octoxinol , Polietilenglicoles/química , Sulfadoxina/análisis , Sulfadoxina/orina , Sulfamerazina/análisis , Sulfamerazina/orina , Sulfatiazol , Sulfatiazoles/análisis , Sulfatiazoles/orina , Agua/análisisRESUMEN
A liquid chromatography-tandem mass spectroscopy (LC-MS/MS) assay was developed and validated to simultaneously quantify anticancer drugs reparixin and paclitaxel in this study. The compounds were extracted from plasma and urine samples by protein precipitation with acetone (supplemented with 0.1% formic acid). Chromatographic separation was achieved using a C18 column, and drug molecules were ionized using dual ion source electrospray and atmospheric pressure chemical ionization (DUIS: ESI-APCI). Reparixin and paclitaxel were quantified using negative and positive multiple reaction monitoring (MRM) mode, respectively. Stable isotope palcitaxel-D5 was used as the internal standard (IS). The assay was validated for specificity, recovery, carryover and sample stability under various storage conditions; it was also successfully applied to measure drug concentrations collected from a pharmacokinetic study in rats. The results confirmed that the assay was accurate and simple in quantifying both reparixin and paclitaxel in plasma and urine with minimal sample pretreatment.
Asunto(s)
Cromatografía Líquida de Alta Presión/métodos , Paclitaxel , Sulfonamidas , Espectrometría de Masas en Tándem/métodos , Animales , Modelos Lineales , Masculino , Paclitaxel/sangre , Paclitaxel/química , Paclitaxel/farmacocinética , Paclitaxel/orina , Ratas , Ratas Sprague-Dawley , Reproducibilidad de los Resultados , Sensibilidad y Especificidad , Sulfonamidas/sangre , Sulfonamidas/química , Sulfonamidas/farmacocinética , Sulfonamidas/orinaRESUMEN
Histone deacetylase inhibitors (HDAC inhibitors) are used to treat malignancies such as cutaneous T cell lymphoma and peripheral T cell lymphoma. Only four drugs are approved by the US Food and Drug Administration, namely vorinostat, romidepsin, panobinostat and belinostat, while chidamide has been approved in China. There are a number of bioanalytical methods reported for the measurement of HDAC inhibitors in clinical (human plasma and serum) and preclinical (mouse plasma, rat plasma, urine and tissue homogenates, etc.) studies. This review covers various HDAC inhibitors such as vorinostat, romidepsin, panobinostat, belinostat and chidamide. In addition to providing a comprehensive review of the available methods for the above mentioned HDAC inhibitors, it also provides case studies with perspectives for chosen drugs. Based on the review, it is concluded that the published methodologies using either HPLC or LC-MS/MS are well suited for the quantification of HDAC inhibitors in various biological fluids to delineate pharmacokinetic data.
Asunto(s)
Cromatografía Líquida de Alta Presión/métodos , Inhibidores de Histona Desacetilasas/farmacocinética , Espectrometría de Masas en Tándem/métodos , Aminopiridinas/sangre , Aminopiridinas/farmacocinética , Aminopiridinas/orina , Animales , Benzamidas/sangre , Benzamidas/farmacocinética , Benzamidas/orina , Depsipéptidos/sangre , Depsipéptidos/farmacocinética , Depsipéptidos/orina , Inhibidores de Histona Desacetilasas/sangre , Inhibidores de Histona Desacetilasas/orina , Humanos , Ácidos Hidroxámicos/sangre , Ácidos Hidroxámicos/farmacocinética , Ácidos Hidroxámicos/orina , Indoles/sangre , Indoles/farmacocinética , Indoles/orina , Neoplasias/tratamiento farmacológico , Panobinostat , Sulfonamidas/sangre , Sulfonamidas/farmacocinética , Sulfonamidas/orina , VorinostatRESUMEN
This article has been retracted: please see Elsevier Policy on Article Withdrawal (https://www.elsevier.com/about/our-business/policies/article-withdrawal). This article has been retracted at the request of Editor following concerns raised by a reader. The article uses several electron micrographs which have been used in other publications as well denoting different samples. Fig. 2A was reused from Fig. 3A, Chemical Engineering Journal, Volume 299, 1 September 2016, Pages 244-254, 10.1016/j.cej.2016.04.051. According to the authors this was due to a mistake at the compilation of the manuscript (mixing images from the GO and Cds:GO samples). Fig. 2C was reused (a lower zoom level) from Fig. 1F, Biosensors and Bioelectronics, Volume 89, Part 1, 15 March 2017, Pages 620-626, 10.1016/j.bios.2015.12.085. The inset in Fig. 1F was reused from Fig. 2D, Environ. Sci. Technol., 2015, 49 (10), pp 61176126, 10.1021/acs.est.5b00182. These problems with the data presented cast doubt on all the data, and accordingly also the conclusions based on that data, in this publication. As such this article represents a severe abuse of the scientific publishing system. The scientific community takes a very strong view on this matter and apologies are offered to readers of the journal that this was not detected during the submission process.
Asunto(s)
Antiinflamatorios no Esteroideos/sangre , Antiinflamatorios no Esteroideos/orina , Grafito/química , Impresión Molecular/métodos , Puntos Cuánticos/química , Sulfonamidas/sangre , Sulfonamidas/orina , Antiinflamatorios no Esteroideos/análisis , Técnicas Biosensibles/métodos , Compuestos de Cadmio/química , Humanos , Límite de Detección , Polímeros/química , Puntos Cuánticos/ultraestructura , Espectrometría de Fluorescencia/métodos , Sulfuros/química , Sulfonamidas/análisisRESUMEN
Venetoclax (ABT-199), a B-cell lymphoma-2 (Bcl-2) protein inhibitor, is currently in clinical development for the treatment of hematologic malignancies. We characterized the absorption, metabolism, and excretion of venetoclax in humans. After a single oral dose of [14C]venetoclax to healthy volunteers, the recovery of total radioactive dose was 100%, with feces being the major route of elimination of the administered dose, whereas urinary excretion was minimal (<0.1%). The extent of absorption was estimated to be at least 65%. Venetoclax was primarily cleared by hepatic metabolism (â¼66% of the administered dose). â¼33% of the administered dose was recovered as the parent drug and its nitro reduction metabolite M30 [2-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-N-((3-amino-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfonyl)-4-(4-((4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)benzamide] (13%) in feces. Biotransformation of venetoclax in humans primarily involves enzymatic oxidation on the dimethyl cyclohexenyl moiety, followed by sulfation and/or nitro reduction. Nitro reduction metabolites were likely formed by gut bacteria. Unchanged venetoclax was the major drug-related material in circulation, representing 72.8% of total plasma radioactivity. M27 (oxidation at the 6 position of cyclohexenyl ring followed by cyclization at the α-carbon of piperazine ring; 4-[(10aR,11aS)-7-(4-chlorophenyl)-9,9-dimethyl-1,3,4,6,8,10,10a,11a-octahydropyrazino[2,1-b][1,3]benzoxazin-2-yl]-N-[3-nitro-4-(tetrahydropyran-4-ylmethylamino)phenyl]sulfonyl-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide) was identified as a major metabolite, representing 12% of total drug-related material. M27 was primarily formed by cytochrome P450 isoform 3A4 (CYP3A4). Steady-state plasma concentrations of M27 in human and preclinical species used for safety testing suggested that M27 is a disproportionate human metabolite. M27 is not expected to have clinically relevant on- or off-target pharmacologic activities.
Asunto(s)
Antineoplásicos/metabolismo , Antineoplásicos/farmacocinética , Compuestos Bicíclicos Heterocíclicos con Puentes/metabolismo , Compuestos Bicíclicos Heterocíclicos con Puentes/farmacocinética , Proteínas Proto-Oncogénicas c-bcl-2/antagonistas & inhibidores , Sulfonamidas/metabolismo , Sulfonamidas/farmacocinética , Absorción Fisiológica , Administración Oral , Antineoplásicos/sangre , Antineoplásicos/orina , Biotransformación , Compuestos Bicíclicos Heterocíclicos con Puentes/sangre , Compuestos Bicíclicos Heterocíclicos con Puentes/orina , Heces/química , Femenino , Voluntarios Sanos , Humanos , Sulfonamidas/sangre , Sulfonamidas/orina , Distribución TisularRESUMEN
Salting-out homogenous extraction followed by ionic liquid/ionic liquid dispersive liquid-liquid micro-extraction system was developed and applied to the extraction of sulfonamides in blood. High-performance liquid chromatography was applied to the determination of the analytes. The blood sample was centrifuged to obtain the serum. After the proteins in the serum were removed in the presence of acetonitrile, ionic liquid 1-butyl-3-methylimidazolium tetrafluoroborate, dipotassium hydrogen phosphate, ionic liquid 1-Hexyl-3-methylimidazolium hexafluorophosphate were added into the resulting solution. After the resulting mixture was ultrasonically shaken and centrifuged, the precipitate was separated. The acetonitrile was added in the precipitate and the analytes were extracted into the acetonitrile phase. The parameters affecting the extraction efficiency, such as volume of ionic liquid, amount of dipotassium hydrogen phosphate, volume of dispersant, extraction time and temperature were investigated. The limits of detection of sulfamethizole (STZ), sulfachlorpyridazine (SCP), sulfamethoxazole (SMX) and Sulfisoxazole (SSZ) were 4.78, 3.99, 5.21 and 3.77µgL-1, respectively. When the present method was applied to the analysis of real blood samples, the recoveries of analytes ranged from 90.0% to 113.0% and relative standard deviations were lower than 7.2%.
Asunto(s)
Antiinfecciosos/sangre , Boratos/química , Imidazoles/química , Líquidos Iónicos/química , Fosfatos/química , Compuestos de Potasio/química , Sulfonamidas/sangre , Animales , Antiinfecciosos/orina , Bovinos , Pollos , Niño , Cromatografía Líquida de Alta Presión , Humanos , Microextracción en Fase Líquida , Conejos , Sulfonamidas/orina , PorcinosRESUMEN
A new simple methodology is proposed for chlorsufuron (CS) traces quantification based upon enhancement of rhodamine B (RhB) fluorescent signal. Experimental variables that influence fluorimetric sensitivity have been studied and optimized. The zeroth order regression calibration was linear from 0.866 to 35.800µgL(-1) CS, with a correlation coefficient of 0.99. At optimal experimental conditions, a limit of detection of 0.259µgL(-1) and a limit of quantification of 0.866µgL(-1) were obtained. The method showed good sensitivity and adequate selectivity and was applied to the determination of trace amounts of CS in plasma, serum and water samples with satisfactory results analyzed by ANOVA test. The proposed methodology represents an alternative to traditional chromatographic techniques for CS monitoring in complex samples, using an accessible instrument in control laboratories.
Asunto(s)
Contaminantes Ambientales/análisis , Colorantes Fluorescentes/química , Plaguicidas/análisis , Rodaminas/química , Sulfonamidas/análisis , Triazinas/análisis , Agua Potable/análisis , Contaminantes Ambientales/sangre , Contaminantes Ambientales/química , Contaminantes Ambientales/orina , Femenino , Fluorescencia , Agua Subterránea/análisis , Humanos , Leche Humana/química , Plaguicidas/sangre , Plaguicidas/química , Plaguicidas/orina , Plasma/química , Suero/química , Espectrometría de Fluorescencia , Sulfonamidas/sangre , Sulfonamidas/química , Sulfonamidas/orina , Triazinas/sangre , Triazinas/química , Triazinas/orinaRESUMEN
BACKGROUND: Due to antibiotic treatment of humans and animals, the prevalence of bacterial resistances increases worldwide. Especially in livestock farming, large quantities of faeces contaminated with antibiotics pose a risk of the carryover of the active ingredient to the environment. Accordingly, the aim of the present study was the evaluation of the benefit of different oral dosage forms (powder, pellets, granula) in pigs concerning the environmental pollution of sulfadiazine. Two subtherapeutic dosages were evaluated in powder mixtures to gain information about their potential to pollute the pig barn. Furthermore, a new group of pigs was kept in the stable after powder feeding of another pig group to determine the possible absorption of environmentally distributed antibiotics. Pigs were orally treated with three dosage forms. Simultaneously, sedimentation and airborne dust were collected and plasma and urine levels were determined. RESULTS: All formulations result in comparable plasma and urine levels, but massive differences in environmental pollution (powder > pellets, granula). Pigs housing in a contaminated barn exhibit traces of sulfadiazine in plasma and urine. CONCLUSION: Using pharmaceutical formulations like pellets or granula, the environmental pollution of sulfonamides can significantly be diminished due to massive dust reduction during feeding.
Asunto(s)
Composición de Medicamentos/veterinaria , Contaminantes Ambientales/análisis , Vivienda para Animales , Sulfonamidas/administración & dosificación , Sulfonamidas/análisis , Administración Oral , Animales , Composición de Medicamentos/normas , Polvo/análisis , Contaminantes Ambientales/sangre , Contaminantes Ambientales/orina , Femenino , Sulfonamidas/sangre , Sulfonamidas/orina , PorcinosRESUMEN
Sulfonamides (SAs) are applied widely as feed additives in the farming of livestock and poultry. It can lead to the excretion of large amounts of SAs in manure and result in persistent environmental pollution. We evaluated the fate of four SAs, sulfamerazine (SM1), sulfachloropyridazine (SCP), sulfadimoxine (SDM') and sulfaquinoxaline (SQ), from oral administration to excretion in urine and feces in pigs. The four SAs were added to homemade feed to make them reach the required concentration gradient, which were 0, 50 and 100 mg/kg (low, normal and high concentrations, respectively). In different treatments, excretions of the four SAs were 35.68-86.88 %. With regard to total excretion, the order was SQ > SCP > SM1 > SDM' for all treatments. The concentration of SAs in the feed had significant effects on the amount of the four SAs excreted every day. The concentration of SAs in feces and in the urine for different treatments was 15.03-26.55 and 14.54-69.22 %, respectively. In each treatment, excretions of SCP, SDM' and SQ in feces were lower than that in urine. The four SAs remained longer in urine than in feces. Excretions in urine and feces were lower if SAs were administered orally rather than by injection.
Asunto(s)
Antibacterianos/análisis , Heces/química , Sulfonamidas/análisis , Medicina Veterinaria , Administración Oral , Animales , Antibacterianos/orina , Cromatografía Líquida de Alta Presión , Extracción en Fase Sólida , Sulfonamidas/administración & dosificación , Sulfonamidas/orina , PorcinosRESUMEN
1. The metabolism of the endothelin receptor antagonist macitentan has been characterized in bile duct-cannulated rats and dogs. 2. In both species, macitentan was metabolized along five primary pathways, i.e. conjugation with glucose (M9), oxidative depropylation (M6), aliphatic hydroxylation (M7), oxidative cleavage of the ethylene glycol linker (M4) and hydrolysis of the sulfamide moiety (M3). Most of the primary metabolites underwent subsequent biotransformation including conjugation with glucuronic acid or glucose, hydrolysis of the sulfamide group or secondary oxidation of the ethylene glycol moiety. 3. Though there were species differences in their relative importance, all metabolic pathways were present in rat and dog. The depropylated M6 was the only metabolite present in plasma of both species. 4. Metabolism was a prerequisite for macitentan excretion as relevant amounts of parent drug were neither detected in bile nor urine. Biliary excretion was the major elimination pathway, while renal elimination was of little importance.
Asunto(s)
Antagonistas de los Receptores de Endotelina/farmacocinética , Pirimidinas/farmacocinética , Sulfonamidas/farmacocinética , Animales , Conductos Biliares/metabolismo , Biotransformación , Cromatografía Líquida de Alta Presión , Perros , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos , Antagonistas de los Receptores de Endotelina/orina , Glicol de Etileno/metabolismo , Femenino , Glucosa/metabolismo , Hepatocitos/metabolismo , Hidroxilación , Masculino , Redes y Vías Metabólicas , Microsomas Hepáticos/metabolismo , Pirimidinas/orina , Ratas , Ratas Wistar , Sulfonamidas/orinaRESUMEN
Organic anion transporting polypeptides (OATPs) mediate hepatic drug uptake and serve as the loci of drug-drug interactions (DDIs). Consequently, there is a major need to develop animal models and refine in vitro-in vivo extrapolations. Therefore, the in vivo disposition of a model OATP substrate, [(3)H]rosuvastatin (RSV), was studied in the cynomolgus monkey and reported for the first time. After monkeys had received a 3-mg/kg oral dose, mass balance was achieved after bile duct cannulation (mean total recovery of radioactivity of 103.6%). Forty-two percent of the RSV dose was recovered in urine and bile, and the elimination pathways were similar to those reported for human subjects; 61.7%, 39.0%, and 2.9% of the dose was recovered in the feces, bile, and urine, respectively. The high levels of unchanged RSV recovered in urine and bile (26% of the dose) and the relatively low levels of metabolites observed indicated that RSV was eliminated largely by excretion. Also, for the first time, the in vitro inhibitory potential of cyclosporin A (CsA) toward cynomolgus monkey OATPs and sodium-taurocholate cotransporting polypeptide was studied in vitro (primary hepatocytes and transporter-transfected cells). It is concluded that one can study the CsA-RSV DDI in the cynomolgus monkey. For example, the in vitro IC50 values were within 2-fold (monkey versus human), and the increase (versus vehicle control) in the RSV AUC0-inf (6.3-fold) and Cmax (10.2-fold) with CsA (100 mg/kg) was similar to that reported for humans. The results further support the use of the cynomolgus monkey as a model to assess interactions involving OATP inhibition.